A Reversal for InflaRx N.V. (IFRX) Is Not Near. The Stock Declines Again

The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 1.71% or $0.67 during the last trading session, reaching $38.83. About 94,661 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 4, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
The move comes after 8 months negative chart setup for the $1.01B company. It was reported on Apr, 4 by Barchart.com. We have $35.72 PT which if reached, will make NASDAQ:IFRX worth $80.64M less.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on February 06, 2019, also Globenewswire.com with their article: “InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors – GlobeNewswire” published on September 21, 2018, Seekingalpha.com published: “InflaRx: Buy The Dip – Seeking Alpha” on June 29, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing – GlobeNewswire” published on October 30, 2018 as well as Globenewswire.com‘s news article titled: “InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results – GlobeNewswire” with publication date: November 21, 2018.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.01 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *